Eye Infections, Bacterial
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Azithromycin T1225
Research Leaders
6 sponsors active, led by Laboratoires Thea
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
29%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (7)
Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine
Steroids for Corneal Ulcers Trial
Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers
Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers
Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers
Research Network
Common Treatments
- Azithromycin T12253
- Azithromycin2
- Hypochlorous Acid1
- Topical Corticosteroid1
- Povidoneiodine1
Active Sponsors
- Laboratoires Thea5
- National Eye Institute (NEI)1
- Thomas M. Lietman1
- Aravind Eye Hospitals, India1
- Dartmouth-Hitchcock Medical Center1
Top Investigators
Centre de Pharmacologie Clinique - Clermont-Ferrand (France)
ASTER, Paris, France
Unité de Pharmacologie Clinique - Clermont-Ferrand (France)
Proctor Foundation, UCSF
Aravind Eye Hospital
Related Conditions
- Corneal Ulcer1